Table 3.
Sensitivity analysis.
| Analysis | Statistical method | I2 | Cochran Q | OR (95% CI) | P | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Leukocyte (I–IV) | FEM | 15% | P=0.29 | 0.46[0.37, 0.55] | P < 0.00001 | ||||||
| Hemoglobin (I–IV) | FEM | 17% | P=0.27 | 0.64[0.53, 0.77] | P < 0.00001 | ||||||
| Platelets (I–IV) | FEM | 7% | P=0.37 | 0.60[0.48, 0.75] | P < 0.00001 | ||||||
| Neutrophils (I–IV) | FEM | 39% | P=0.15 | 0.62[0.43, 0.90] | P=0.01 | ||||||
| Leukocyte (III–IV) | FEM | 43% | P=0.05 | 0.46[0.35, 0.62] | P < 0.00001 | ||||||
| Hemoglobin (III–IV) | FEM | 0% | P=0.94 | 0.57[0.36, 0.92] | P=0.02 | ||||||
| Platelets (III–IV) | FEM | 12% | P=0.33 | 0.60[0.36, 1.00] | P=0.05 | ||||||
| Neutrophils (III–IV) | FEM | 0% | P=0.68 | 0.73[0.41, 1.31] | P=0.30 | ||||||
| Sensitivity analysis via excluding the under- or overestimated trials | |||||||||||
| Analysis | Trials | OR (95% CI) | I2 | Excluded studies [Reference] | Trials | OR (95% CI) | I2 | ||||
| Neutrophils (I–IV) | 6 | 0.62[0.43, 0.90] | 39% | Sun et al., 2006 | 5 | 0.51[0.34, 0.78] | 10% | ||||
| Leukocyte (III–IV) | 13 | 0.46[0.35,0.62] | 43% | Sun et al., 2006 | 12 | 0.38[0.28, 0.52] | 0% | ||||
| Platelets (III–IV) | 9 | 0.60[0.36, 1.00] | 12% | Sun et al., 2006 | 8 | 0.54[0.31, 0.92] | 0% | ||||
| Neutrophils (III–IV) | 3 | No statistical significance | |||||||||